Studies on rat liver phosphatidate phosphohydrolase and plasma lipids

Effect of HMG-CoA reductase inhibitors

Elisabet Humble, Ayman Al-Shurbaji, Erik Lund, Lars Berglund

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Normolipidemic rats were treated with HMG-CoA reductase inhibitors (lovastatin or pravastatin) for periods of 1-3 days. Administration of these drugs reduced plasma triacylglycerol levels. Lovastatin-treated rats displayed a 30% lower hepatic triacylglycerol secretion rate compared to controls as estimated using Triton WR-1339. Lovastatin in a dose of 0.1% in the diet for 3 days increased hepatic phosphatidate phosphohydrolase (PAP) activity 2- to 3-fold, both in the cytosolic and microsomal fractions. Similar effects were seen in the presence of 0.2% pravastatin. PAP in both fractions was stimulated to a lesser extent by treatment with 0.1% pravastatin. These differences in PAP activity obtained by different treatment regimens were preserved during purification of cytosolic PAP on hydroxylapatite. The increase in PAP activity upon treatment with lovastatin or pravastatin was gradual and occurred simultaneously with the apparent increase in HMG-CoA reductase activity. In rats treated with the reductase inhibitors, the activity of microsomal and cytosolic PAP was inversely correlated to plasma triacylglycerol levels. The results indicate that hepatic triacylglycerol and cholesterol synthesis might be co-ordinately regulated, and also suggest that the activity of PAP is rapidly modulated in concert with changes in plasma triacylglycerol levels.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalBiochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism
Volume1214
Issue number1
DOIs
StatePublished - Aug 25 1994
Externally publishedYes

Fingerprint

Phosphatidate Phosphatase
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver
Rats
Pravastatin
Lovastatin
Lipids
Plasmas
Triglycerides
Hydroxymethylglutaryl CoA Reductases
Durapatite
Nutrition
Purification
Oxidoreductases
Cholesterol
Diet

Keywords

  • HMG-CoA reductase
  • Lovastatin
  • Phosphatidate phosphohydrolase
  • Pravastatin
  • Triacylglycerol
  • VLDL

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Endocrinology

Cite this

Studies on rat liver phosphatidate phosphohydrolase and plasma lipids : Effect of HMG-CoA reductase inhibitors. / Humble, Elisabet; Al-Shurbaji, Ayman; Lund, Erik; Berglund, Lars.

In: Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, Vol. 1214, No. 1, 25.08.1994, p. 32-38.

Research output: Contribution to journalArticle

@article{0ca138003c534a51a300ae07b27aff0c,
title = "Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: Effect of HMG-CoA reductase inhibitors",
abstract = "Normolipidemic rats were treated with HMG-CoA reductase inhibitors (lovastatin or pravastatin) for periods of 1-3 days. Administration of these drugs reduced plasma triacylglycerol levels. Lovastatin-treated rats displayed a 30{\%} lower hepatic triacylglycerol secretion rate compared to controls as estimated using Triton WR-1339. Lovastatin in a dose of 0.1{\%} in the diet for 3 days increased hepatic phosphatidate phosphohydrolase (PAP) activity 2- to 3-fold, both in the cytosolic and microsomal fractions. Similar effects were seen in the presence of 0.2{\%} pravastatin. PAP in both fractions was stimulated to a lesser extent by treatment with 0.1{\%} pravastatin. These differences in PAP activity obtained by different treatment regimens were preserved during purification of cytosolic PAP on hydroxylapatite. The increase in PAP activity upon treatment with lovastatin or pravastatin was gradual and occurred simultaneously with the apparent increase in HMG-CoA reductase activity. In rats treated with the reductase inhibitors, the activity of microsomal and cytosolic PAP was inversely correlated to plasma triacylglycerol levels. The results indicate that hepatic triacylglycerol and cholesterol synthesis might be co-ordinately regulated, and also suggest that the activity of PAP is rapidly modulated in concert with changes in plasma triacylglycerol levels.",
keywords = "HMG-CoA reductase, Lovastatin, Phosphatidate phosphohydrolase, Pravastatin, Triacylglycerol, VLDL",
author = "Elisabet Humble and Ayman Al-Shurbaji and Erik Lund and Lars Berglund",
year = "1994",
month = "8",
day = "25",
doi = "10.1016/0005-2760(94)90006-X",
language = "English (US)",
volume = "1214",
pages = "32--38",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Studies on rat liver phosphatidate phosphohydrolase and plasma lipids

T2 - Effect of HMG-CoA reductase inhibitors

AU - Humble, Elisabet

AU - Al-Shurbaji, Ayman

AU - Lund, Erik

AU - Berglund, Lars

PY - 1994/8/25

Y1 - 1994/8/25

N2 - Normolipidemic rats were treated with HMG-CoA reductase inhibitors (lovastatin or pravastatin) for periods of 1-3 days. Administration of these drugs reduced plasma triacylglycerol levels. Lovastatin-treated rats displayed a 30% lower hepatic triacylglycerol secretion rate compared to controls as estimated using Triton WR-1339. Lovastatin in a dose of 0.1% in the diet for 3 days increased hepatic phosphatidate phosphohydrolase (PAP) activity 2- to 3-fold, both in the cytosolic and microsomal fractions. Similar effects were seen in the presence of 0.2% pravastatin. PAP in both fractions was stimulated to a lesser extent by treatment with 0.1% pravastatin. These differences in PAP activity obtained by different treatment regimens were preserved during purification of cytosolic PAP on hydroxylapatite. The increase in PAP activity upon treatment with lovastatin or pravastatin was gradual and occurred simultaneously with the apparent increase in HMG-CoA reductase activity. In rats treated with the reductase inhibitors, the activity of microsomal and cytosolic PAP was inversely correlated to plasma triacylglycerol levels. The results indicate that hepatic triacylglycerol and cholesterol synthesis might be co-ordinately regulated, and also suggest that the activity of PAP is rapidly modulated in concert with changes in plasma triacylglycerol levels.

AB - Normolipidemic rats were treated with HMG-CoA reductase inhibitors (lovastatin or pravastatin) for periods of 1-3 days. Administration of these drugs reduced plasma triacylglycerol levels. Lovastatin-treated rats displayed a 30% lower hepatic triacylglycerol secretion rate compared to controls as estimated using Triton WR-1339. Lovastatin in a dose of 0.1% in the diet for 3 days increased hepatic phosphatidate phosphohydrolase (PAP) activity 2- to 3-fold, both in the cytosolic and microsomal fractions. Similar effects were seen in the presence of 0.2% pravastatin. PAP in both fractions was stimulated to a lesser extent by treatment with 0.1% pravastatin. These differences in PAP activity obtained by different treatment regimens were preserved during purification of cytosolic PAP on hydroxylapatite. The increase in PAP activity upon treatment with lovastatin or pravastatin was gradual and occurred simultaneously with the apparent increase in HMG-CoA reductase activity. In rats treated with the reductase inhibitors, the activity of microsomal and cytosolic PAP was inversely correlated to plasma triacylglycerol levels. The results indicate that hepatic triacylglycerol and cholesterol synthesis might be co-ordinately regulated, and also suggest that the activity of PAP is rapidly modulated in concert with changes in plasma triacylglycerol levels.

KW - HMG-CoA reductase

KW - Lovastatin

KW - Phosphatidate phosphohydrolase

KW - Pravastatin

KW - Triacylglycerol

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=0028071598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028071598&partnerID=8YFLogxK

U2 - 10.1016/0005-2760(94)90006-X

DO - 10.1016/0005-2760(94)90006-X

M3 - Article

VL - 1214

SP - 32

EP - 38

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

IS - 1

ER -